SlideShare a Scribd company logo
Patient Care in Pharmacy
Practice
Anas Bahnassi PhD
Anas Bahnassi PhD CDM CDE 2
Patient-Centered Care
Care centered on patients’ needs
and expectations
3Anas Bahnassi PhD CDM CDE
Goals of
Pharmaceutical Care
Cure of a disease
Elimination or reduction of a patient’s
symptoms
Arresting or slowing of a disease process
Preventing a disease or symptomatology
4Anas Bahnassi PhD CDM CDE
The central component of
Pharmaceutical Care is:
CARING ABOUT THE PATIENT.
5Anas Bahnassi PhD CDM CDE
Pharmaceutical Care
Process
Initiate
relationship with
the patient or
caregiver
Gather patient
information
(subjective and
objective)
Assess info
(patient
assessment)
Develop
pharmaceutical
care plan
Complete
InterventionImplement
follow-up
6Anas Bahnassi PhD CDM CDE
Primary Elements of
Pharmaceutical Care
The need of the society
to address Drug
Related Problems
(DRPs) A patient-centered
approach to
meet this need
A practice based on
“caring”
about and for patients
Responsibility for
finding and
responding to the
patient’s DRPs
7Anas Bahnassi PhD CDM CDE
Pharmacist responsibility in
Pharmaceutical Care
To ensure that the patient’s drug therapy is appropriately
indicated, the most effective available, the safest possible, the
most convenient to take, and the most economical
To identify, resolve, and prevent any DRPs
To ensure that the patient’s therapeutic goals are met and that
optimal health-related outcomes are attained.
8Anas Bahnassi PhD CDM CDE
Drug Related Problems
DRPs
– To resolve identified DTPs and to prevent future
problems, pharmacist must understand the causes of
these problems.
– The pharmacist must use a consistent, systematic and
comprehensive process Pharmaceutical Care
process
DRP is any undesirable event experienced by the
patient that involves drug therapy and that actually
(or potentially) interferes with a desired patient
outcome.
9Anas Bahnassi PhD CDM CDE
Common DRPs
and Their causes
DRP Type Possible Causes
Unnecessary Drug
Prescribed
No Indication
Duplicate Therapy
Wrong Drug Contraindications present
Drug not indicated for conditions
More effective medic. available
Drug interaction
Indication refractory to drug
Inappropriate dosage form
Dose Too Low Wrong dose
Inappropriate frequency
Inappropriate duration
Incorrect storage
Incorrect administration
Drug interaction 10Anas Bahnassi PhD CDM CDE
Common DRPs
and Their causes
DRP Type Possible Causes
Dose Too High Wrong dose
Inappropriate frequency
Inappropriate duration
Incorrect administration
Drug interaction
Adverse Drug Reactions Undesirable drug side effect
Allergic reaction
Drug interaction
Incorrect administration
Dose changed too quickly
Unsafe drug for the patient
11Anas Bahnassi PhD CDM CDE
Common DRPs
and Their causes
DRP Type Possible Causes
Noncompliance Cannot afford drug
Doesn’t understand instructions on how to take
the drug
Cannot swallow/administer the drug
Drug not available
Additional drug therapy Untreated condition
Prophylactic therapy
Synergistic therapy
12Anas Bahnassi PhD CDM CDE
Pharmaceutical Care
Process
• Initiating a relationship with the patient
– patient bringing a new prescription to the pharmacy
or asking about a nonprescription drug
• Pharmacist gathers all the pertinent information
to evaluate the patient’s health and drug therapy
appropriately
– subjective information (patient complaints and
symptoms)
– objective information (medication profile, vital signs,
or physical assessment data)
13Anas Bahnassi PhD CDM CDE
Pharmaceutical Care
Process
• Pharmacist assess the information and looks for
DRPs.
• The DTPs are prioritized along with corresponding
goals and goal criteria, and documented in
pharmaceutical care plan (PCP)
• Integral to the PCP, pharmacist develop the
solutions to DRPs (= interventions).
• Develop the monitoring plan, which outlines
factors that will determine attainment of the
desired patient outcomes (BP measurement, lab
data, talking with patient).
14Anas Bahnassi PhD CDM CDE
Pharmaceutical Care
Process
• Implement follow-up, which includes
implementing the monitoring plan (ex. Contact
the patient to evaluate drug therapy compliance
or drug side effects). Other follow up may
include measuring vital signs or checking other
physical or lab data.
NOTE:
• Ideally, the patient should be involved throughout the entire
pharmaceutical care process.
• After that plan has been implemented, the PCP recycles once again. The
pharmacist gather more data, assess the Px progress, and adjust the
plan.
15Anas Bahnassi PhD CDM CDE
For successfully incorporate
Pharmaceutical Care into
Practice, the Pharmacist
must have knowledge and
skills in Patient
Assessment
16Anas Bahnassi PhD CDM CDE
Patient Assessment
Patient assessment is the process
through which the pharmacist evaluate
the patient information (both objective
and subjective) that was gathered from
the patient and other sources (e.g. drug
therapy profile, medical record, etc.)
17Anas Bahnassi PhD CDM CDE
Patient Assessment
Means:
Making
decisions
regarding:
1. The health status of the
patient.
2. Drug therapy needs and
problems.
3. Interventions that will
resolve identified drug
problems and future
problems
4. Follow-up to ensure that
patient outcomes are
being met.
18Anas Bahnassi PhD CDM CDE
Purpose of
Patient Assessment:
A pharmacist cannot
adequately provide
pharmaceutical care
without assessing
patients.
• To identify,
• To resolve, and
• To prevent drug
related problems.
19Anas Bahnassi PhD CDM CDE
Patient Assessment
Should be done by:
• Asking a series of questions:
• These questions will guide the pharmacist
through the assessment process.
• Assess the patient’s physical
conditions:
• e g. skin abnormalities, obtainment of
vital signs, peak flow readings, blood
glucose levels, cholesterol values.
20Anas Bahnassi PhD CDM CDE
Documentation:
• Provides a permanent record of patient
information.
• Provides a permanent record and evidence of
pharmaceutical care activities by the pharmacist.
• Communicates essential
information to other pharmacists
and health care professionals.
• Serves as a legal record of patient
care that was provided.
• Provides back-up for billing
purposes.
21Anas Bahnassi PhD CDM CDE
Characteristics of
Useful Patient Records:
• Information that is neat, organized, and able to be found
quickly.
• Information that is easily understandable, so that any health
care professional can determine what the problems were,
what actions were taken, and what follow-up is needed.
• Accurate subjective and objective information.
• An assessment of the patient
information, focusing on DRPs.
• A plan to resolve any problems that
were identified.
• A plan for future follow-up to ensure that any problems are
resolved and that patient outcomes are met.
22Anas Bahnassi PhD CDM CDE
SOAP Note
23Anas Bahnassi PhD CDM CDE
SOAP Note:
Subjective:
Includes information that
is given by the patient,
family members,
significant others, or
care givers.
• Complaint/symptoms in his/her
own words
• Recent history that pertains ti
those symptoms (history of
present illness)
• Past medical history
• Medication history, including
compliance & ADRs.
• Allergies
• Social and/or family history
• Review of systems.
This type of
information contains:
24Anas Bahnassi PhD CDM CDE
SOAP Note:
Objective:
Includes data that are
obtained from the
patient and that can
be measured objectively.
• Vital signs.
• Physical findings or physical
examination (if possible).
• Laboratory test results (if
available).
• Serum drug concentrations (if
available).
• Various diagnostic test results (if
available).
• Computerized medication profile
with refill information (if
available).
This type of
information contains:
25Anas Bahnassi PhD CDM CDE
SOAP Note:
Assessment:
• Analyzes subjective and objective
information.
• Determines the health status of
the patient.
• Is the patient experiencing a
DRP?
• Have the patient’s outcomes
been met?
• Provides the basis and rationale
for the plan.
The
pharmacist:
26Anas Bahnassi PhD CDM CDE
SOAP Note:
Plan:
• Actions that were—or need to be—
taken to resolve any problems that
have been identified.
• Follow-up to ensure that problems
are actually corrected and that
future problems do not develop.
• The follow-up should include
monitoring parameters that
need to be assessed as well as
the interval for the next
assessments
It involves:
27Anas Bahnassi PhD CDM CDE
SOAP Note:
Plan:
• Guidelines should be done with
the data at the time of the
follow-up.
• Simplicity and reproducibility:
• A colleague should be able to
read, interpret, and act on
the plan if the pharmacist
who documented the note is
not available.
It involves:
28Anas Bahnassi PhD CDM CDE
Pharmaceutical
Care Plan:
Name: M.H
Gender: F
Date: 9/2/2014
Complaint: HTN.
Drugs Used:
Atenolol 25mg QD.
Captopril 12.5mg
BID
• The patient is picking up her
Atenolol Rx.
• She feels:
• Head lightness.
• Weakness.
• Impaired balance for 2 weeks.
• She has been taking Atenolol BID
instead of QD this week.
Subjective:
29Anas Bahnassi PhD CDM CDE
Pharmaceutical
Care Plan:
Name: M.H
Gender: F
Date: 9/2/2014
Complaint: HTN.
Drugs Used:
Atenolol 25mg QD.
Captopril 12.5mg
BID
• The patient was staggering at the
pharmacy counter.
• Pulse is: 48 bpm.
• Blood pressure is:
114/72 mm Hg
112/70 mm Hg
Objective:
30Anas Bahnassi PhD CDM CDE
Pharmaceutical
Care Plan:
Name: M.H
Gender: F
Date: 9/2/2014
Complaint: HTN.
Drugs Used:
Atenolol 25mg QD.
Captopril 12.5mg
BID
• Bradycardia and hypotension-
new-onset may be due
noncompliance with atenolol
dosing.
Assessment:
31Anas Bahnassi PhD CDM CDE
Pharmaceutical
Care Plan:
Name: M.H
Gender: F
Date: 9/2/2014
Complaint: HTN.
Drugs Used:
Atenolol 25mg QD.
Captopril 12.5mg
BID
• Inform the patient to take
atenolol once a day with
breakfast and captopril 2 times
daily as usual.
• For the follow-up a week later
recheck pulse and blood
pressure.
• If still low, ask her to contact
her doctor and suggest
lowering the dose atenolol.
Plan:
32Anas Bahnassi PhD CDM CDE
Clinical Pharmacy VI:
First Aid
Anas Bahnassi PhD CDM CDE
abahnassi@gmail.com
http://www.twitter.com/abpharm
http://www.facebook.com/pharmaprof
http://www.linkedin.com/in/abahnassi

More Related Content

What's hot

Drug Therapy Monitiring
Drug Therapy MonitiringDrug Therapy Monitiring
Drug Therapy Monitiring
maneeshkumar reddy
 
Clinical pharmacy services
Clinical pharmacy servicesClinical pharmacy services
Clinical pharmacy services
Rafi Bhat
 
Sources of drug information
Sources of drug informationSources of drug information
Sources of drug information
Sumit Kumar
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
KRUSHNA ZAMBARE
 
Pharmacy practice
Pharmacy practicePharmacy practice
Pharmacy practice
Asraful Islam Rayhan
 
Patient counselling
Patient counsellingPatient counselling
Patient counselling
Ramesh Ganpisetti
 
Strategies to overcome barriers of patient counselling
Strategies to overcome barriers of patient counsellingStrategies to overcome barriers of patient counselling
Strategies to overcome barriers of patient counselling
Ramesh Ganpisetti
 
General Discussion on Clinical Pharmacy
General Discussion on Clinical Pharmacy  General Discussion on Clinical Pharmacy
General Discussion on Clinical Pharmacy
Jahangirnagar University
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
Dr. Ramesh Bhandari
 
Hospital and its organisation, BUDGET AND pHARMACY AND tHERAPEUTIC COMMITTEE
Hospital and its organisation, BUDGET AND pHARMACY AND tHERAPEUTIC COMMITTEEHospital and its organisation, BUDGET AND pHARMACY AND tHERAPEUTIC COMMITTEE
Hospital and its organisation, BUDGET AND pHARMACY AND tHERAPEUTIC COMMITTEE
Sanju Kaladharan
 
Medication history Interview
Medication history InterviewMedication history Interview
Medication history Interview
Dr. Ramesh Bhandari
 
medication adherence
medication adherencemedication adherence
medication adherence
Ramesh Ganpisetti
 
Ward round participation
Ward round participationWard round participation
Ward round participation
Dr. Ramesh Bhandari
 
Barriers of patient counseling in a community pharmacy and Strategies to over...
Barriers of patient counseling in a community pharmacy and Strategies to over...Barriers of patient counseling in a community pharmacy and Strategies to over...
Barriers of patient counseling in a community pharmacy and Strategies to over...
MerrinJoseph1
 
DRUG INFORMATION RESOURCES.pptx
DRUG INFORMATION RESOURCES.pptxDRUG INFORMATION RESOURCES.pptx
DRUG INFORMATION RESOURCES.pptx
PunamGauchan1
 
Drug Therapy Monitoring
Drug Therapy MonitoringDrug Therapy Monitoring
Drug Therapy Monitoring
Dr. Ramesh Bhandari
 
Dispensing errors and Its Prevention
Dispensing errors and Its PreventionDispensing errors and Its Prevention
Dispensing errors and Its Prevention
anamsohail29
 
Patient counselling clinical pharmacy
Patient counselling clinical pharmacyPatient counselling clinical pharmacy
Patient counselling clinical pharmacy
Dr Asish Kumar Saha
 
Legality of prescription..pptx
Legality of prescription..pptxLegality of prescription..pptx
Legality of prescription..pptx
Sumit Tiwari
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
Prejith Philip Chacko
 

What's hot (20)

Drug Therapy Monitiring
Drug Therapy MonitiringDrug Therapy Monitiring
Drug Therapy Monitiring
 
Clinical pharmacy services
Clinical pharmacy servicesClinical pharmacy services
Clinical pharmacy services
 
Sources of drug information
Sources of drug informationSources of drug information
Sources of drug information
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
 
Pharmacy practice
Pharmacy practicePharmacy practice
Pharmacy practice
 
Patient counselling
Patient counsellingPatient counselling
Patient counselling
 
Strategies to overcome barriers of patient counselling
Strategies to overcome barriers of patient counsellingStrategies to overcome barriers of patient counselling
Strategies to overcome barriers of patient counselling
 
General Discussion on Clinical Pharmacy
General Discussion on Clinical Pharmacy  General Discussion on Clinical Pharmacy
General Discussion on Clinical Pharmacy
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
 
Hospital and its organisation, BUDGET AND pHARMACY AND tHERAPEUTIC COMMITTEE
Hospital and its organisation, BUDGET AND pHARMACY AND tHERAPEUTIC COMMITTEEHospital and its organisation, BUDGET AND pHARMACY AND tHERAPEUTIC COMMITTEE
Hospital and its organisation, BUDGET AND pHARMACY AND tHERAPEUTIC COMMITTEE
 
Medication history Interview
Medication history InterviewMedication history Interview
Medication history Interview
 
medication adherence
medication adherencemedication adherence
medication adherence
 
Ward round participation
Ward round participationWard round participation
Ward round participation
 
Barriers of patient counseling in a community pharmacy and Strategies to over...
Barriers of patient counseling in a community pharmacy and Strategies to over...Barriers of patient counseling in a community pharmacy and Strategies to over...
Barriers of patient counseling in a community pharmacy and Strategies to over...
 
DRUG INFORMATION RESOURCES.pptx
DRUG INFORMATION RESOURCES.pptxDRUG INFORMATION RESOURCES.pptx
DRUG INFORMATION RESOURCES.pptx
 
Drug Therapy Monitoring
Drug Therapy MonitoringDrug Therapy Monitoring
Drug Therapy Monitoring
 
Dispensing errors and Its Prevention
Dispensing errors and Its PreventionDispensing errors and Its Prevention
Dispensing errors and Its Prevention
 
Patient counselling clinical pharmacy
Patient counselling clinical pharmacyPatient counselling clinical pharmacy
Patient counselling clinical pharmacy
 
Legality of prescription..pptx
Legality of prescription..pptxLegality of prescription..pptx
Legality of prescription..pptx
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
 

Similar to Lecture one: Patient Assessment in Pharmacy Practice

1 The pharmacist’s Role in Self Care.pptx
1 The pharmacist’s Role in Self Care.pptx1 The pharmacist’s Role in Self Care.pptx
1 The pharmacist’s Role in Self Care.pptx
DrAllaAddinAlsyany
 
PCN 612 PATIENT DATA EVALUATION.pptx
PCN 612 PATIENT DATA EVALUATION.pptxPCN 612 PATIENT DATA EVALUATION.pptx
PCN 612 PATIENT DATA EVALUATION.pptx
StevenABaqrEgili
 
PHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docxPHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docx
NbkKarim1
 
Workshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcaseWorkshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcaseaaltunalboro
 
Mitigating Risk When Managing High Dose, Chronic Pain Patients
Mitigating Risk When Managing High Dose, Chronic Pain Patients Mitigating Risk When Managing High Dose, Chronic Pain Patients
Mitigating Risk When Managing High Dose, Chronic Pain Patients
Polsinelli PC
 
Pharmacy practice.pdf
Pharmacy practice.pdfPharmacy practice.pdf
Pharmacy practice.pdf
UVAS
 
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
BU School of Medicine
 
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshRx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
OPUNITE
 
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreinerRx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
OPUNITE
 
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01pmppowerpoint
 
RDP-CP-PP.pdf
RDP-CP-PP.pdfRDP-CP-PP.pdf
RDP-CP-PP.pdf
rishi2789
 
Patient adherence – what’s the problem?
Patient adherence – what’s the problem?Patient adherence – what’s the problem?
Patient adherence – what’s the problem?PM Society
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
Brahmani baachu
 
Rx15 pdmp wed_300_1_stripp_2lev-lucas
Rx15 pdmp wed_300_1_stripp_2lev-lucasRx15 pdmp wed_300_1_stripp_2lev-lucas
Rx15 pdmp wed_300_1_stripp_2lev-lucas
OPUNITE
 
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01pmppowerpoint
 
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01pmppowerpoint
 
Intentional re-challenge and the clinical data management of Drug Related pro...
Intentional re-challenge and the clinical data management of Drug Related pro...Intentional re-challenge and the clinical data management of Drug Related pro...
Intentional re-challenge and the clinical data management of Drug Related pro...
ClinosolIndia
 
Clinical pharmacy ppt
Clinical pharmacy pptClinical pharmacy ppt
Clinical pharmacy ppt
Nabi Hasan
 
Point of Care
Point of CarePoint of Care
Point of Caregrowell
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
Shreyas Patel
 

Similar to Lecture one: Patient Assessment in Pharmacy Practice (20)

1 The pharmacist’s Role in Self Care.pptx
1 The pharmacist’s Role in Self Care.pptx1 The pharmacist’s Role in Self Care.pptx
1 The pharmacist’s Role in Self Care.pptx
 
PCN 612 PATIENT DATA EVALUATION.pptx
PCN 612 PATIENT DATA EVALUATION.pptxPCN 612 PATIENT DATA EVALUATION.pptx
PCN 612 PATIENT DATA EVALUATION.pptx
 
PHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docxPHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docx
 
Workshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcaseWorkshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcase
 
Mitigating Risk When Managing High Dose, Chronic Pain Patients
Mitigating Risk When Managing High Dose, Chronic Pain Patients Mitigating Risk When Managing High Dose, Chronic Pain Patients
Mitigating Risk When Managing High Dose, Chronic Pain Patients
 
Pharmacy practice.pdf
Pharmacy practice.pdfPharmacy practice.pdf
Pharmacy practice.pdf
 
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
 
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshRx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
 
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreinerRx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
 
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01
 
RDP-CP-PP.pdf
RDP-CP-PP.pdfRDP-CP-PP.pdf
RDP-CP-PP.pdf
 
Patient adherence – what’s the problem?
Patient adherence – what’s the problem?Patient adherence – what’s the problem?
Patient adherence – what’s the problem?
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
 
Rx15 pdmp wed_300_1_stripp_2lev-lucas
Rx15 pdmp wed_300_1_stripp_2lev-lucasRx15 pdmp wed_300_1_stripp_2lev-lucas
Rx15 pdmp wed_300_1_stripp_2lev-lucas
 
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
 
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
 
Intentional re-challenge and the clinical data management of Drug Related pro...
Intentional re-challenge and the clinical data management of Drug Related pro...Intentional re-challenge and the clinical data management of Drug Related pro...
Intentional re-challenge and the clinical data management of Drug Related pro...
 
Clinical pharmacy ppt
Clinical pharmacy pptClinical pharmacy ppt
Clinical pharmacy ppt
 
Point of Care
Point of CarePoint of Care
Point of Care
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
 

More from Anas Bahnassi أنس البهنسي

Lecture nine cardiovascular_emeregencies
Lecture nine cardiovascular_emeregenciesLecture nine cardiovascular_emeregencies
Lecture nine cardiovascular_emeregencies
Anas Bahnassi أنس البهنسي
 
Urinary Tract Infections
Urinary Tract InfectionsUrinary Tract Infections
Urinary Tract Infections
Anas Bahnassi أنس البهنسي
 
Pneumonia
PneumoniaPneumonia
Influenza
InfluenzaInfluenza
Acute bronchitis
Acute bronchitisAcute bronchitis
Sinusitis
SinusitisSinusitis
Streptococccal sore throat
Streptococccal sore throatStreptococccal sore throat
Streptococccal sore throat
Anas Bahnassi أنس البهنسي
 
Acute Otitis Media
Acute Otitis Media Acute Otitis Media
Principles of infectious diseases
Principles of infectious diseasesPrinciples of infectious diseases
Principles of infectious diseases
Anas Bahnassi أنس البهنسي
 
Pharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part OnePharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part OneAnas Bahnassi أنس البهنسي
 
Rheumatoid arthritis Part 2
Rheumatoid arthritis Part 2Rheumatoid arthritis Part 2
Rheumatoid arthritis Part 2
Anas Bahnassi أنس البهنسي
 
Rheumatoid Arthritis Part !
Rheumatoid Arthritis Part !Rheumatoid Arthritis Part !
Rheumatoid Arthritis Part !
Anas Bahnassi أنس البهنسي
 
Pharmacotherapy of Diabetes: Part 2
Pharmacotherapy of Diabetes: Part 2Pharmacotherapy of Diabetes: Part 2
Pharmacotherapy of Diabetes: Part 2
Anas Bahnassi أنس البهنسي
 
Role of community pharmacists in diabetes management
Role of community pharmacists in diabetes managementRole of community pharmacists in diabetes management
Role of community pharmacists in diabetes management
Anas Bahnassi أنس البهنسي
 
Diabetes Care: Part One
Diabetes Care: Part OneDiabetes Care: Part One
Diabetes Care: Part One
Anas Bahnassi أنس البهنسي
 
Premixed insulin dosing in actual practice
Premixed insulin dosing in actual practicePremixed insulin dosing in actual practice
Premixed insulin dosing in actual practice
Anas Bahnassi أنس البهنسي
 

More from Anas Bahnassi أنس البهنسي (20)

Lecture nine cardiovascular_emeregencies
Lecture nine cardiovascular_emeregenciesLecture nine cardiovascular_emeregencies
Lecture nine cardiovascular_emeregencies
 
Urinary Tract Infections
Urinary Tract InfectionsUrinary Tract Infections
Urinary Tract Infections
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Influenza
InfluenzaInfluenza
Influenza
 
Acute bronchitis
Acute bronchitisAcute bronchitis
Acute bronchitis
 
Sinusitis
SinusitisSinusitis
Sinusitis
 
Streptococccal sore throat
Streptococccal sore throatStreptococccal sore throat
Streptococccal sore throat
 
Acute Otitis Media
Acute Otitis Media Acute Otitis Media
Acute Otitis Media
 
Principles of infectious diseases
Principles of infectious diseasesPrinciples of infectious diseases
Principles of infectious diseases
 
Lecture three management cycle Part 3
Lecture three management cycle Part 3Lecture three management cycle Part 3
Lecture three management cycle Part 3
 
Lecture two management cycle Part: 2
Lecture two management cycle Part: 2Lecture two management cycle Part: 2
Lecture two management cycle Part: 2
 
Pharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part OnePharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part One
 
Osteoarthritis
OsteoarthritisOsteoarthritis
Osteoarthritis
 
Juvenile idiopathic arthritis
Juvenile idiopathic arthritisJuvenile idiopathic arthritis
Juvenile idiopathic arthritis
 
Rheumatoid arthritis Part 2
Rheumatoid arthritis Part 2Rheumatoid arthritis Part 2
Rheumatoid arthritis Part 2
 
Rheumatoid Arthritis Part !
Rheumatoid Arthritis Part !Rheumatoid Arthritis Part !
Rheumatoid Arthritis Part !
 
Pharmacotherapy of Diabetes: Part 2
Pharmacotherapy of Diabetes: Part 2Pharmacotherapy of Diabetes: Part 2
Pharmacotherapy of Diabetes: Part 2
 
Role of community pharmacists in diabetes management
Role of community pharmacists in diabetes managementRole of community pharmacists in diabetes management
Role of community pharmacists in diabetes management
 
Diabetes Care: Part One
Diabetes Care: Part OneDiabetes Care: Part One
Diabetes Care: Part One
 
Premixed insulin dosing in actual practice
Premixed insulin dosing in actual practicePremixed insulin dosing in actual practice
Premixed insulin dosing in actual practice
 

Recently uploaded

Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
BhavyaRajput3
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 

Recently uploaded (20)

Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 

Lecture one: Patient Assessment in Pharmacy Practice

  • 1. Patient Care in Pharmacy Practice Anas Bahnassi PhD
  • 2. Anas Bahnassi PhD CDM CDE 2
  • 3. Patient-Centered Care Care centered on patients’ needs and expectations 3Anas Bahnassi PhD CDM CDE
  • 4. Goals of Pharmaceutical Care Cure of a disease Elimination or reduction of a patient’s symptoms Arresting or slowing of a disease process Preventing a disease or symptomatology 4Anas Bahnassi PhD CDM CDE
  • 5. The central component of Pharmaceutical Care is: CARING ABOUT THE PATIENT. 5Anas Bahnassi PhD CDM CDE
  • 6. Pharmaceutical Care Process Initiate relationship with the patient or caregiver Gather patient information (subjective and objective) Assess info (patient assessment) Develop pharmaceutical care plan Complete InterventionImplement follow-up 6Anas Bahnassi PhD CDM CDE
  • 7. Primary Elements of Pharmaceutical Care The need of the society to address Drug Related Problems (DRPs) A patient-centered approach to meet this need A practice based on “caring” about and for patients Responsibility for finding and responding to the patient’s DRPs 7Anas Bahnassi PhD CDM CDE
  • 8. Pharmacist responsibility in Pharmaceutical Care To ensure that the patient’s drug therapy is appropriately indicated, the most effective available, the safest possible, the most convenient to take, and the most economical To identify, resolve, and prevent any DRPs To ensure that the patient’s therapeutic goals are met and that optimal health-related outcomes are attained. 8Anas Bahnassi PhD CDM CDE
  • 9. Drug Related Problems DRPs – To resolve identified DTPs and to prevent future problems, pharmacist must understand the causes of these problems. – The pharmacist must use a consistent, systematic and comprehensive process Pharmaceutical Care process DRP is any undesirable event experienced by the patient that involves drug therapy and that actually (or potentially) interferes with a desired patient outcome. 9Anas Bahnassi PhD CDM CDE
  • 10. Common DRPs and Their causes DRP Type Possible Causes Unnecessary Drug Prescribed No Indication Duplicate Therapy Wrong Drug Contraindications present Drug not indicated for conditions More effective medic. available Drug interaction Indication refractory to drug Inappropriate dosage form Dose Too Low Wrong dose Inappropriate frequency Inappropriate duration Incorrect storage Incorrect administration Drug interaction 10Anas Bahnassi PhD CDM CDE
  • 11. Common DRPs and Their causes DRP Type Possible Causes Dose Too High Wrong dose Inappropriate frequency Inappropriate duration Incorrect administration Drug interaction Adverse Drug Reactions Undesirable drug side effect Allergic reaction Drug interaction Incorrect administration Dose changed too quickly Unsafe drug for the patient 11Anas Bahnassi PhD CDM CDE
  • 12. Common DRPs and Their causes DRP Type Possible Causes Noncompliance Cannot afford drug Doesn’t understand instructions on how to take the drug Cannot swallow/administer the drug Drug not available Additional drug therapy Untreated condition Prophylactic therapy Synergistic therapy 12Anas Bahnassi PhD CDM CDE
  • 13. Pharmaceutical Care Process • Initiating a relationship with the patient – patient bringing a new prescription to the pharmacy or asking about a nonprescription drug • Pharmacist gathers all the pertinent information to evaluate the patient’s health and drug therapy appropriately – subjective information (patient complaints and symptoms) – objective information (medication profile, vital signs, or physical assessment data) 13Anas Bahnassi PhD CDM CDE
  • 14. Pharmaceutical Care Process • Pharmacist assess the information and looks for DRPs. • The DTPs are prioritized along with corresponding goals and goal criteria, and documented in pharmaceutical care plan (PCP) • Integral to the PCP, pharmacist develop the solutions to DRPs (= interventions). • Develop the monitoring plan, which outlines factors that will determine attainment of the desired patient outcomes (BP measurement, lab data, talking with patient). 14Anas Bahnassi PhD CDM CDE
  • 15. Pharmaceutical Care Process • Implement follow-up, which includes implementing the monitoring plan (ex. Contact the patient to evaluate drug therapy compliance or drug side effects). Other follow up may include measuring vital signs or checking other physical or lab data. NOTE: • Ideally, the patient should be involved throughout the entire pharmaceutical care process. • After that plan has been implemented, the PCP recycles once again. The pharmacist gather more data, assess the Px progress, and adjust the plan. 15Anas Bahnassi PhD CDM CDE
  • 16. For successfully incorporate Pharmaceutical Care into Practice, the Pharmacist must have knowledge and skills in Patient Assessment 16Anas Bahnassi PhD CDM CDE
  • 17. Patient Assessment Patient assessment is the process through which the pharmacist evaluate the patient information (both objective and subjective) that was gathered from the patient and other sources (e.g. drug therapy profile, medical record, etc.) 17Anas Bahnassi PhD CDM CDE
  • 18. Patient Assessment Means: Making decisions regarding: 1. The health status of the patient. 2. Drug therapy needs and problems. 3. Interventions that will resolve identified drug problems and future problems 4. Follow-up to ensure that patient outcomes are being met. 18Anas Bahnassi PhD CDM CDE
  • 19. Purpose of Patient Assessment: A pharmacist cannot adequately provide pharmaceutical care without assessing patients. • To identify, • To resolve, and • To prevent drug related problems. 19Anas Bahnassi PhD CDM CDE
  • 20. Patient Assessment Should be done by: • Asking a series of questions: • These questions will guide the pharmacist through the assessment process. • Assess the patient’s physical conditions: • e g. skin abnormalities, obtainment of vital signs, peak flow readings, blood glucose levels, cholesterol values. 20Anas Bahnassi PhD CDM CDE
  • 21. Documentation: • Provides a permanent record of patient information. • Provides a permanent record and evidence of pharmaceutical care activities by the pharmacist. • Communicates essential information to other pharmacists and health care professionals. • Serves as a legal record of patient care that was provided. • Provides back-up for billing purposes. 21Anas Bahnassi PhD CDM CDE
  • 22. Characteristics of Useful Patient Records: • Information that is neat, organized, and able to be found quickly. • Information that is easily understandable, so that any health care professional can determine what the problems were, what actions were taken, and what follow-up is needed. • Accurate subjective and objective information. • An assessment of the patient information, focusing on DRPs. • A plan to resolve any problems that were identified. • A plan for future follow-up to ensure that any problems are resolved and that patient outcomes are met. 22Anas Bahnassi PhD CDM CDE
  • 24. SOAP Note: Subjective: Includes information that is given by the patient, family members, significant others, or care givers. • Complaint/symptoms in his/her own words • Recent history that pertains ti those symptoms (history of present illness) • Past medical history • Medication history, including compliance & ADRs. • Allergies • Social and/or family history • Review of systems. This type of information contains: 24Anas Bahnassi PhD CDM CDE
  • 25. SOAP Note: Objective: Includes data that are obtained from the patient and that can be measured objectively. • Vital signs. • Physical findings or physical examination (if possible). • Laboratory test results (if available). • Serum drug concentrations (if available). • Various diagnostic test results (if available). • Computerized medication profile with refill information (if available). This type of information contains: 25Anas Bahnassi PhD CDM CDE
  • 26. SOAP Note: Assessment: • Analyzes subjective and objective information. • Determines the health status of the patient. • Is the patient experiencing a DRP? • Have the patient’s outcomes been met? • Provides the basis and rationale for the plan. The pharmacist: 26Anas Bahnassi PhD CDM CDE
  • 27. SOAP Note: Plan: • Actions that were—or need to be— taken to resolve any problems that have been identified. • Follow-up to ensure that problems are actually corrected and that future problems do not develop. • The follow-up should include monitoring parameters that need to be assessed as well as the interval for the next assessments It involves: 27Anas Bahnassi PhD CDM CDE
  • 28. SOAP Note: Plan: • Guidelines should be done with the data at the time of the follow-up. • Simplicity and reproducibility: • A colleague should be able to read, interpret, and act on the plan if the pharmacist who documented the note is not available. It involves: 28Anas Bahnassi PhD CDM CDE
  • 29. Pharmaceutical Care Plan: Name: M.H Gender: F Date: 9/2/2014 Complaint: HTN. Drugs Used: Atenolol 25mg QD. Captopril 12.5mg BID • The patient is picking up her Atenolol Rx. • She feels: • Head lightness. • Weakness. • Impaired balance for 2 weeks. • She has been taking Atenolol BID instead of QD this week. Subjective: 29Anas Bahnassi PhD CDM CDE
  • 30. Pharmaceutical Care Plan: Name: M.H Gender: F Date: 9/2/2014 Complaint: HTN. Drugs Used: Atenolol 25mg QD. Captopril 12.5mg BID • The patient was staggering at the pharmacy counter. • Pulse is: 48 bpm. • Blood pressure is: 114/72 mm Hg 112/70 mm Hg Objective: 30Anas Bahnassi PhD CDM CDE
  • 31. Pharmaceutical Care Plan: Name: M.H Gender: F Date: 9/2/2014 Complaint: HTN. Drugs Used: Atenolol 25mg QD. Captopril 12.5mg BID • Bradycardia and hypotension- new-onset may be due noncompliance with atenolol dosing. Assessment: 31Anas Bahnassi PhD CDM CDE
  • 32. Pharmaceutical Care Plan: Name: M.H Gender: F Date: 9/2/2014 Complaint: HTN. Drugs Used: Atenolol 25mg QD. Captopril 12.5mg BID • Inform the patient to take atenolol once a day with breakfast and captopril 2 times daily as usual. • For the follow-up a week later recheck pulse and blood pressure. • If still low, ask her to contact her doctor and suggest lowering the dose atenolol. Plan: 32Anas Bahnassi PhD CDM CDE
  • 33. Clinical Pharmacy VI: First Aid Anas Bahnassi PhD CDM CDE abahnassi@gmail.com http://www.twitter.com/abpharm http://www.facebook.com/pharmaprof http://www.linkedin.com/in/abahnassi